一、董事会会议召开情况 南京伟思医疗科技股份有限公司（以下简称"公司"）第四届董事会第七次 会议通知于 2025 年 12 月 12 日以书面方式向全体董事发出。会议于 2025 年 12 月 17 日以现场结合通讯方式在公司会议室召开。 证券代码：688580 证券简称：伟思医疗 公告编号：2025-044 南京伟思医疗科技股份有限公司 第四届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次会议由董事长王志愚先生召集并主持，会议应到董事 7 人，实到董事 7 人，公司全体高级管理人员列席了会议。本次会议的召集、召开程序符合《中华 人民共和国公司法》等相关法律、行政法规、规范性文件及《南京伟思医疗科技 股份有限公司章程》的有关规定。 二、董事会会议审议情况 （一）审议通过《关于部分募投项目结项并将节余募集资金永久补充流动 资金的议案》 鉴于公司 IPO 时募投项目—康复设备组装调试项目、信息化建设项目基本建 设完毕并投入使用，同意公司予以结项，并将节余募集资金用于永久补充流动资 金。 特此公告 ...

Core Viewpoint - The company, Weisi Medical (688580.SH), has approved the conclusion of certain fundraising projects and plans to permanently supplement its working capital with the remaining funds from these projects [1] Group 1: Fundraising Projects - The company has decided to conclude the fundraising projects "Rehabilitation Equipment Assembly and Debugging Project" and "Information Technology Construction Project" [1] - The total remaining funds from these projects amount to 36.9774 million yuan [1] Group 2: Use of Remaining Funds - The remaining funds will be used to permanently supplement the company's working capital for daily operations and business development [1] - The actual amount used will be based on the balance of the fundraising account on the day of the fund transfer [1] - The company plans to cancel the fundraising account following this transfer [1]

证券日报网讯12月16日，伟思医疗在互动平台回答投资者提问时表示，截至2025年9月30日，公司股东 总户数为8098户。 ...

Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology sector, with a focus on specific companies such as Innovent Biologics, Efang Biologics, and Mindray Medical [4][27]. Core Insights - The report emphasizes the investment opportunities in the "One Old, One Young" sectors, particularly in reproductive assistance, pediatric drugs and vaccines, maternal and infant health monitoring, and aging-related consumer healthcare [2][24]. - It highlights the importance of clinical value in the pharmaceutical sector, suggesting that future investments should focus on innovative drug chains and high-end medical devices [3][25]. - The report notes that the domestic pharmaceutical sector is experiencing a valuation recovery, driven by supportive policies and increasing global competitiveness [26]. Summary by Sections Market Review - The A-share pharmaceutical index fell by 1.04%, underperforming the CSI 300 index by 0.96 percentage points and the ChiNext index by 2.52 percentage points, ranking 17th among 31 sub-industries [1][15]. - The Hong Kong Hang Seng Medical Health Index decreased by 2.26%, lagging behind the Hang Seng Index by 0.97 percentage points [1][15]. R&D Progress - Recent developments include IND applications from Haisimengnuo and clinical trial advancements for various drugs from companies like Hengrui Medicine and Anke Biotechnology [29][30]. Key Companies and Valuation - The report provides a detailed earnings forecast and valuation table for key companies, indicating a positive outlook for companies like WuXi AppTec and Mindray Medical, with projected PE ratios decreasing over the next few years [4][27]. Policy and Industry Resonance - The report discusses the eight key tasks for medical insurance in 2026, focusing on improving coverage for flexible employment and enhancing maternal healthcare services, which are expected to boost the birth rate and the rehabilitation medical device industry [2][20][24]. Investment Strategy - The report suggests a three-stage investment strategy based on clinical value, recommending investments in innovative drugs and high-value medical devices, with a focus on companies that are expanding internationally [3][25][26].

从细分产品单点突破，到依托技术同源横向拓展，是不少中国企业的成长路径。成立于2001年的伟思医疗，就是沿着这一 路径发展。从国内盆底及产后康复领域的领先者，到"康复＋医美"双轮驱动，再到在脑机接口等前沿技术方向探索，公司 实现了单一业务到多元布局的产品线跨越。 医疗器械市场空间巨大，随着老龄化速度加快、慢性病管理需求增加，市场需求持续增长。然而"红海"的另一面是，医疗 器械也是一个"长坡厚雪"的赛道，研发投入大、回报周期长，对于企业而言是耐心和战略的考验。 盆底及产后康复，是伟思医疗的起家业务，也是公司最重要的"护城河"之一。2009年起，在中国盆底康复市场还处于萌芽 期时，伟思医疗就持续投入研发，先后搭建了电刺激、磁刺激、电生理等核心技术平台，并成功推出了盆底功能磁刺激仪 等多款核心产品。公司先后进入精神心理康复、盆底及产后康复、神经康复等核心赛道，形成差异化优势。 ◎记者 操子怡 不过，随着企业规模扩大，传统的业务市场容量逐渐显露天花板，公司开始思考：能否把磁刺激、电刺激等底层技术用于 更多治疗场景？ 她表示，近三年来，公司研发投入比例稳定在15%以上，处于行业较高水平。此外，公司很多产品集中于精神疾病诊 ...

Core Viewpoint - Weisi Medical emphasizes its commitment to research and innovation as the driving force behind its competitive advantage in the rehabilitation medical device sector [1] Group 1: Company Overview - Weisi Medical is a technology-driven enterprise in the domestic rehabilitation medical device field, focusing on continuous R&D investment and precise market positioning [1] - The company has established significant competitive advantages in various niche markets, maintaining excellent profitability and market share [1] Group 2: Product Coverage and Market Position - The company's products cover a wide range of domestic medical institutions, including general hospitals, obstetrics, psychiatry, pediatrics, and rehabilitation specialty hospitals [1] - In key niche markets such as pelvic and postpartum rehabilitation, mental health, and pediatric rehabilitation, Weisi Medical ranks among the top domestic manufacturers [1] - Core products like transcranial magnetic stimulators, pelvic magnetic stimulators, and group biofeedback devices are leading in market sales compared to similar products [1] Group 3: Future Strategy - Looking ahead, the company plans to strengthen its R&D engine, accelerate the localization of high-end equipment, and deepen the layout of rehabilitation clinical solutions [1] - The goal is to consolidate its position as a technology leader in the industry and to drive the overall upgrade of China's rehabilitation medical industry [1]

Core Viewpoint - Weisi Medical (688580) has experienced a decline in stock price, with a current market capitalization of 4.587 billion yuan, ranking 79th in the medical device sector and 3616th in the A-share market [1] Group 1: Stock Performance - As of November 14, 2025, Weisi Medical's stock closed at 47.9 yuan, down 2.68% from the previous week [1] - The stock reached a high of 50.25 yuan on November 10 and a low of 47.36 yuan on November 13 [1] Group 2: Shareholder Changes - On November 12, 2025, Weisi Medical announced that shareholder Nanjing Zhida Venture Capital Center (Limited Partnership) reduced its holdings by 448,600 shares, accounting for 0.4684% of the total share capital, during a period when the stock price fell by 7.58% [2] - From August 14 to November 11, 2025, the same shareholder reduced its holdings by a total of 1,176,782 shares, representing 1.2287% of the total share capital, with a reduction price range of 45.00 to 57.50 yuan per share, totaling approximately 59.52 million yuan [3][4] - The shareholder's stake decreased from 8.29% to 7.06%, and the actual reduction aligned with the previously disclosed plan [3][4]

Trading Information Summary - On November 12, 2025, Weisi Medical (688580) closed at 48.2 yuan, with a slight increase of 0.06% and a turnover rate of 1.97% [1] - The trading volume was 18,800 shares, with a total transaction value of 91.6083 million yuan [1] - On the same day, the net inflow of main funds was 15.4231 million yuan, accounting for 16.84% of the total transaction value [3] Shareholder Changes - On November 12, 2025, Weisi Medical announced that shareholder Nanjing Zhida Venture Capital Center (Limited Partnership) reduced its holdings by 448,600 shares between November 5 and November 11, representing 0.4684% of the company's total share capital [2] - The share price during this period decreased by 7.58%, closing at 48.17 yuan on November 11 [2] - From August 14 to November 11, the shareholder cumulatively reduced its holdings by 1,176,782 shares, accounting for 1.2287% of the total share capital, with a reduction price range of 45.00 to 57.50 yuan per share, totaling approximately 59.516 million yuan [2][3]

Core Viewpoint - The announcement details the completion of a share reduction plan by a major shareholder of Weisi Medical, indicating the amount and method of shares sold, as well as the overall impact on the company's total share capital [1][3]. Summary by Sections Shareholder Reduction Overview - The shareholder, Nanjing Zhida Venture Capital Center (Limited Partnership), held 7,935,120 shares prior to the reduction, representing 8.29% of the total share capital of Weisi Medical [2]. Implementation Results of the Reduction Plan - The reduction plan was disclosed on July 23, 2025, with a timeframe set from August 14, 2025, to November 11, 2025. The shareholder planned to reduce up to 2,873,137 shares, which would account for a maximum of 3% of the total share capital. This included a maximum of 957,712 shares through centralized bidding (1% of total shares) and 1,915,425 shares through block trading (2% of total shares) [3]. - The actual reduction results showed that from August 14 to November 11, 2025, the shareholder reduced 956,052 shares through centralized bidding (0.9983% of total shares) and 220,730 shares through block trading (0.2305% of total shares), totaling 1,176,782 shares, which is 1.2287% of the total share capital [3][4]. Additional Information - The reduction plan was fully implemented as planned, with no early termination of the plan [4].

Core Viewpoint - Weisi Medical announced the completion of the share reduction plan by its shareholder Nanjing Zhida Venture Capital Center (Limited Partnership) on November 12, as confirmed in a response to investor inquiries on the interactive platform [1] Group 1 - The share reduction plan by Nanjing Zhida Venture Capital Center has reached its deadline and is now concluded [1]